330 results about "Antiinflammatory Effect" patented technology

The invention discloses an application of anemoside B4 used as an immunomodulator to drugs for treating acute inflammations. The anti-inflammatory effect of the anemoside B4 is directly produced through inhibition of lymphocyte activation and inflammatory factor secretion. The application of the anemoside B4 used as the immunomodulator to the drugs for treating acute inflammations is disclosed for the first time, and the anemoside B4 belongs to a purely natural preparation, is safe, reliable and free of side effects and has potential development value for the drugs for treating acute inflammations.

The present invention has an object to provide an external dermatological formulation having satisfactory blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing effect, hair nourishing effect, emusifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and/or transdermal absorption-promoting effect with a satisfactory safety and skin feeling; The object is solved by providing an external dermatological formulation comprising a saccharide derivative of α,α-trehalose and one or more members selected from substances having any one of blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing efect, hair nourishing effect, emulsifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and transdermal absorption-promoting effect.

The invention belongs to the field of biological medicines, and particularly discloses a mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and a preparing method for the preparation. The preparation is composed of umbilical cord or placenta mesenchymal stem cells and cytokines, as well as hyaluronate which is used for bearing the umbilical cord or placenta mesenchymal stem cells and cytokines and has the slow-release and anti-inflammatory effects; and the preparation is injected into a part of the endometrium and ovary in a targeted manner to be slowly released and absorbed. The curative effect of repairing the ovary and endometrium can be achieved, functional ovulation can be promoted, the premature ovarian failures can be treated, and the various perimenopausal syndromes can be remitted. Compared with an existing intravenous re-transfusion and intervention path, untoward effects of intravenous transfusion are avoided through the preparation and a using method of the preparation, abdomen and local wounds caused by interventional treatment are avoided, and side effects and hurts caused by treatment to a patient can be effectively prevented, so that the preparation is safer and more effective, is high in practicability and easy to popularize, and has the huge application value.

The invention relates to the technical field of functional food, and discloses a composite probiotic composition and application thereof. The probiotic composition comprises, by weight, 1-25 parts ofbacterial probiotic, 1-15 parts of yeast probiotic and 20-70 parts of prebiotic. The probiotic composition can be effectively colonized in the oral cavity and the intestine to regulate the micro-ecology of the flora in the oral cavity and the intestine, exert antibacterial and anti-inflammatory effects and improve various oral discomforts and intestine uncomfortable symptoms caused by imbalance ofthe flora. At the same time, the health condition of the oral cavity and the intestine can be improved, and the composition can be used for preparing products for improving, preventing and treating oral or intestine discomforts.

The invention discloses a novel heptacyclic compound (2'S,5'S)-tetrahydropyrazine [1',2':1,6] and bis{2,3,4,9-tetrahydro-1H-pyridine [3,4-b] indole}-1',4'-diketone (THPDTPI for short), a preparation method thereof, and antithrombosis action, anti-inflammatory action, anti-tumor action, free radical scavenging action and P-selectin expression inhibition action thereof. Therefore, the invention discloses application of the THPDTPI in preparing a medicament which takes the P-selectin as a target and simultaneously inhibits thrombosis, inflammation and tumor. Because thrombosis and inflammation are the most popular complications in patients with tumor, the THPDTPI not only can treat tumor, but also can prevent patients with tumor from complicating thrombosis and inflammation. The THPDTPI disclosed by the invention has favorable clinical application prospects.

N-Arylphenylacetamide derivatives represented by the following formula [I]: (wherein R<1 >is C1-6 alkoxy, etc.; R<2 >is hydrogen, -(CH2)m-N(R<6>)(R<7>) (m is an integer of from 1 to 4; R<6 >is hydrogen, C1-4 alkyl, etc., R<7 >is hydrogen, etc.), etc.; R<3 >is hydrogen, halogen, etc.; R<4 >is C6-10 alkyl, -Y-R<8 >(Y is a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc., R<8 >is aryl, C3-8 cycloalkyl, C6-15 polycycloalkyl, etc.), etc.; R<5 >is hydrogen, etc.; and X<1 >is hydrogen), or pharmaceutically acceptable salts thereof or hydrates or solvates of the same, and a pharmaceutical composition containing the same. These compounds are useful as preventives and/or remedies giving no pain at the early stage of administration, which are efficacious in oral administration and have potent analgesic and antiinflammatory effects.

Pharmacological test shows that the externally-used preparation of Cetirizine has ideal allergy resistant and anti-inflammatory action to the rat passive cutaneous anaphylaxis (Rat PCA) model and dimethylbenzene caused mouse otitis model, and also prevents the adverse effect to the central system caused by whole body administration. It is also found in the test, that the externally used preparation of Cetirizine also has very fine inhibitory action to dinitrofluorobenzene caused mouse porphyria hypersensitivity (PTH), the novel pharmacological action of the Cetirizine shows that the Cetirizine external preparation has good therapeutic action to skin inflammations which mainly include porphyria hypersensitivity.

The invention relates to conjugates of saturated aliphatic chain alcohol, dexamethasone, and Glu-Asp-Gly, preparation, a nano structure, and applications thereof. The invention discloses 6 saturated aliphatic chain alcohol modified dexamethasone-Glu-Asp-Gly conjugates represented by the formula 10 a-f, wherein in the formula the n represents 7, 9, 11, 13, 15, or 17. The invention also discloses a preparation method, a nano structure, immunity inhibition activity, inflammation inhibition activity, and pain relieving activity of the conjugates. The invention also finds that the conjugates do not have any side effect leading to osteoporosis. The researches on the inhibition effect of the conjugates on splenic lymphocyte mitogen proliferation reactions and the survival time after mouse retroauricular cardiac muscle transplant show that the conjugates have an excellent immunity inhibition effect. The researches on the effect of the conjugates on the swelling degree of mouse ears which are inflamed due to xylene show that the conjugates have an excellent anti-inflammation effect. The researches on the effect of the conjugates on mouse heat radiation tail flick time show that the conjugates have an excellent pain-relieving effect. The researches on the effect of the conjugates on the mouse thigh bones show that the conjugates cannot cause osteoporosis. So the conjugates have a wide application prospect in the preparation of immunity inhibition drugs.

The present invention relates to 1-aza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

Medicinal compositions characterized by containing fudosteine and an antipyretic/analgesic. These medicinal compositions are medicinal compositions to be used for common cold, etc. which have improved sputum-removal and antiinflammatory effects.

The invention provides a preparation method of a malan straw extract, a malan straw product, a pharmaceutical composition and an application thereof. The preparation method comprises the following steps: selecting a right amount of malan straw, crushing into coarse powder or intermediate powder, extracting 2-3 times by decoction in water or by ethanol/petroleum ether refluxing with 1-2 hours for each time, filtering, merging the filtrates, concentrating, and drying to obtain the malan straw extract. The preparation process of the malan straw extract is simple and practicable, and the obtained extract has obvious anti-inflammatory effect and pain-relieving effect and shows good effects for treating hepatitis, gynecologic inflammation, inflammation of urinary system, pneumonia and nephritis diseases, thereby achieving favorable application prospects.

The invention discloses a medicine for treating tracheitis and bronchitis and a preparation method thereof. The natural botanical drugs chosen by the invention comprise peucedanum root, white mulberry bark, loquat leaf, bitter apricot seed, ephedra, baikal skullcap root, etc. The medicine of the invention has the efficacies of clearing away the lung-heat to purge heat, resolving phlegm to relieve cough, preventing asthma and sending down abnormally ascending. Tests and studies indicate that the medicine of the invention has obvious anti-infectious effects on the infection of mice caused by staphylococcus aureus and has obvious inhibitory action on ear dwelling caused by xylene and on leg dwelling of rats caused by 1% carrageenin, which indicates that the medicine has obvious anti-inflammatory action; in addition, the medicine of the invention has obvious effects on relieving cough, resolving phlegm and relieving asthma, which can be used for treating tracheitis and bronchitis in clinical practice.

The invention discloses application of a glutaminase inhibitor in preparation of a medicine for treating psoriasis. In-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, including remarkably reducing the Baker score of skin lesion, effectively reducing the epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing the medicine for treating psoriasis.

A patch for transdermal administration having a sufficiently high transdermal permeation property of a COX-2 inhibitor to exert a superior antiinflammatory effect, the patch for transdermal administration comprising a backing and an adhesive layer which is placed on at least one side of the backing and comprises an adhesive base agent and a drug, wherein the drug is valdecoxib or a pharmaceutically acceptable salt thereof.

The present invention relates to reduction of side effects of diclofenac or a salt thereof An agent for reducing side effects of diclofenac or a salt thereof which comprises ornoprostil. It is expected that a combination agent of diclofenac or a non-toxic salt thereof and ornoprostil is comparable to even superior to marketed diclofenac tablets or Arthrotec tables in effects and fast-acting property while showing little side effects (particularly digestive disorders, gastric ulcer, diarrhea/vomiting and renal disorder) and exerting excellent antipyretic, analgesic and antiinlfammatory effects. Also, by formulating the combination agent into a preparation of separation type pharmaceutical preparation, the stability of ornoprostil can be improved.

The invention relates to a medicinal composition for treating canker sore and local infection of body surface and reducing inflammation, a product and application thereof. The medicinal composition comprises aminoglycoside antibiotics, local anaesthetics and glucocorticoids in weight ratio of (0.1-10):(1-10):(0.01-10). Compared with the prior art, the medicinal composition has the advantages that local anaesthetics can alleviate pains of patients in time; antibiotics has the antibiotic effect of treating infection caused by bacteria; and the glucocorticoids has the anti-inflammatory effect of reducing focus hyperemia, reducing permeability of capillary and inhibiting inflammatory cells from transferring to the inflammatory part; and the synergistic action of the three medicaments promotes the healing of canker sore so as to achieve good treatment effect.

The invention relates to the technical field of medicines, in particular to an application of an xanthiazone compound in preparing a drug for preventing or treating rheumatoid arthritis. A formula ofthe xanthiazone compound is shown as follows as shown in the specification. The compound significantly inhibits NO generation for RAW264.7 inflammatory cells and fibroblast-like synoviocytes stimulated by LPS (lipopolysaccharide), and has an obvious inhibiting effect on mouse ear swelling caused by dimethylbenzene and the rheumatoid arthritis induced by collagen, and an obvious swelling diminishing and anti-inflammatory effect on rat toe swelling due to inflammation caused by a Freund adjuvant; and therefore, the compound can be used for preventing and treating the rheumatoid arthritis.

The invention discloses an externally used compound preparation. The preparation comprises bioactive hyaluronic acid with anti-inflammatory activity, and also comprises an antimicrobial medicine or 8-50[mu]g/ml of cortical hormone, and the antimicrobial medicine is an antifungal agent and/or an antibacterial medicine. The bioactive hyaluronic acid with anti-inflammatory activity in the preparation substitutes all or most cortical hormone, and contains no or a small amount of the cortical hormone, so side effects brought by the cortical hormone are avoided or greatly reduced. The bioactive hyaluronic acid with anti-inflammatory activity can be compounded with the antifungal agent and/or the antibacterial medicine, so the preparation has antifungal and/or antibacterial curative effects, and can effectively treat gum, nasal mucosa and skin diseases.

The invention belongs to the technical field of skin light damage repair, and discloses application of exosome secreted by a human umbilical cord mesenchymal stem cell to preparation of a medicine forrepairing skin ultraviolet injury. The umbilical cord mesenchymal stem cell exosome is a natural vesica, so that the immunogenicity is lower. Meanwhile, the exosome has functions of oxidation resistance, antiinflammatory effect, proliferation, apoptosis inhibition, collagen synthesis and the like similar to the functions of a parent cell in tissue regeneration repair, and can play a role in skinprotection in multiple ways. Therefore, the exosome hopefully become an alternative strategy for decellularization treatment, and has important clinic application prospect and market transformation value in multiple skin regeneration related diseases.

The invention provides allyl-containing monocarbonyl curcumin analogs with antiinflammatory actions. In addition, the invention also provides a pharmaceutical composition of the compounds, antiinflammatory application and the like.